BIOMAT Database Logo BIOMAT Database Logo

Anti-topoisomerase I antibodies in systemic lupus erythematosus as a marker of severe nephritis. 2006

Mohamed A Hamidou, and Marie A Audrain, and Agathe Masseau, and Christian Agard, and Anne Moreau
Department of Internal Medicine, University Hospital Hôtel-Dieu, Place Alexis Ricordeau, 44 035, Nantes, France. mohamed.hamidou@chu-nantes.fr

The authors report nine patients with systemic lupus erythematosus associated with anti-topoisomerase I antibodies (ELISA test) without features of systemic sclerosis. These antibodies were correlated with the disease activity and might be a marker of the severity of the closely related to difusse proliferative glomerulonephritis.

UI MeSH Term Description Entries
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D008297 Male Males
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D004264 DNA Topoisomerases, Type I DNA TOPOISOMERASES that catalyze ATP-independent breakage of one of the two strands of DNA, passage of the unbroken strand through the break, and rejoining of the broken strand. DNA Topoisomerases, Type I enzymes reduce the topological stress in the DNA structure by relaxing the superhelical turns and knotted rings in the DNA helix. DNA Nicking-Closing Protein,DNA Relaxing Enzyme,DNA Relaxing Protein,DNA Topoisomerase,DNA Topoisomerase I,DNA Topoisomerase III,DNA Topoisomerase III alpha,DNA Topoisomerase III beta,DNA Untwisting Enzyme,DNA Untwisting Protein,TOP3 Topoisomerase,TOP3alpha,TOPO IIIalpha,Topo III,Topoisomerase III,Topoisomerase III beta,Topoisomerase IIIalpha,Topoisomerase IIIbeta,DNA Nicking-Closing Proteins,DNA Relaxing Enzymes,DNA Type 1 Topoisomerase,DNA Untwisting Enzymes,DNA Untwisting Proteins,Topoisomerase I,Type I DNA Topoisomerase,III beta, Topoisomerase,III, DNA Topoisomerase,III, Topo,III, Topoisomerase,IIIalpha, TOPO,IIIalpha, Topoisomerase,IIIbeta, Topoisomerase,Topoisomerase III, DNA,Topoisomerase, TOP3,beta, Topoisomerase III
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D005921 Glomerulonephritis Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY. Bright Disease,Kidney Scarring,Glomerulonephritides,Scarring, Kidney
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Mohamed A Hamidou, and Marie A Audrain, and Agathe Masseau, and Christian Agard, and Anne Moreau
Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus.
February 2001, Arthritis and rheumatism,
Mohamed A Hamidou, and Marie A Audrain, and Agathe Masseau, and Christian Agard, and Anne Moreau
Significance of Anti-C1q Antibodies in Patients with Systemic Lupus Erythematosus as A Marker of Disease Activity and Lupus Nephritis.
January 2016, The Egyptian journal of immunology,
Mohamed A Hamidou, and Marie A Audrain, and Agathe Masseau, and Christian Agard, and Anne Moreau
[Anti-Sm antibodies--marker antibodies in systemic lupus erythematosus (SLE)].
June 2002, Zeitschrift fur Rheumatologie,
Mohamed A Hamidou, and Marie A Audrain, and Agathe Masseau, and Christian Agard, and Anne Moreau
Plasma C4d as marker for lupus nephritis in systemic lupus erythematosus.
December 2017, Arthritis research & therapy,
Mohamed A Hamidou, and Marie A Audrain, and Agathe Masseau, and Christian Agard, and Anne Moreau
Anti-topoisomerase-I antibodies in systemic lupus erythematosus and potential association with the presence of anti-dsDNA antibodies.
September 2017, Lupus,
Mohamed A Hamidou, and Marie A Audrain, and Agathe Masseau, and Christian Agard, and Anne Moreau
Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy.
May 2003, Annals of the rheumatic diseases,
Mohamed A Hamidou, and Marie A Audrain, and Agathe Masseau, and Christian Agard, and Anne Moreau
Anti-neutrophil cytoplasmic antibodies in new-onset systemic lupus erythematosus and lupus nephritis.
August 2008, Inflammation,
Mohamed A Hamidou, and Marie A Audrain, and Agathe Masseau, and Christian Agard, and Anne Moreau
Anti-nucleosome antibodies as a disease activity marker in patients with systemic lupus erythematosus.
July 2009, International journal of rheumatic diseases,
Mohamed A Hamidou, and Marie A Audrain, and Agathe Masseau, and Christian Agard, and Anne Moreau
Systemic Lupus Erythematosus and Lupus Nephritis Presenting as Severe Constitutional Symptoms.
March 2024, Cureus,
Mohamed A Hamidou, and Marie A Audrain, and Agathe Masseau, and Christian Agard, and Anne Moreau
Systemic lupus erythematosus and nephritis: severe relapse with disappearance of antinuclear antibodies.
July 1980, British medical journal,
Copied contents to your clipboard!